UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study

The lancet oncology, 2009-03, Vol.10 (3), p.247-257

2009

Volltextzugriff (PDF)

Thyroid cancer: burden of illness and management of disease

Journal of Cancer, 2011-01, Vol.2 (1), p.193-199

2011

Volltextzugriff (PDF)

American Cancer Society Head and Neck Cancer Survivorship Care Guideline

CA: a cancer journal for clinicians, 2016-05, Vol.66 (3), p.203-239

2016

Volltextzugriff (PDF)

Role of B Cells in Responses to Checkpoint Blockade Immunotherapy and Overall Survival of Cancer Patients

Clinical cancer research, 2021-11, Vol.27 (22), p.6075-6082

2021

Volltextzugriff (PDF)

Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas

Clinical cancer research, 2015-02, Vol.21 (3), p.632-641

2015

Volltextzugriff (PDF)

Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer

Cancer, 2016-12, Vol.122 (24), p.3856-3864

2016

Volltextzugriff (PDF)

Role of molecular markers in the management of head and neck cancers

Current opinion in oncology, 2011-05, Vol.23 (3), p.259-264

2011

Volltextzugriff (PDF)

Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer

JCI insight, 2017-09, Vol.2 (18)

2017

Volltextzugriff (PDF)

Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies

Head & neck oncology, 2011-07, Vol.3 (1), p.31-31, Article 31

2011

Volltextzugriff (PDF)

Lenvatinib in Advanced, Radioactive Iodine-Refractory, Differentiated Thyroid Carcinoma

Clinical cancer research, 2015-12, Vol.21 (24), p.5420-5426

2015

Volltextzugriff (PDF)

Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: TrilynX phase III study design

Future oncology (London, England), 2022-05, Vol.18 (14), p.1669-1678

2022

Volltextzugriff (PDF)

Modifiable risk behaviors in patients with head and neck cancer

Cancer, 2013-07, Vol.119 (13), p.2419-2426

2013

Volltextzugriff (PDF)

Single sample expression-anchored mechanisms predict survival in head and neck cancer

PLoS computational biology, 2012-01, Vol.8 (1), p.e1002350-e1002350

2012

Volltextzugriff (PDF)

Diarrhea associated with afatinib: an oral ErbB family blocker

Expert review of anticancer therapy, 2013-06, Vol.13 (6), p.729-736

2013

Volltextzugriff (PDF)

Phase II Trial of Gefitinib 250 mg Daily in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

Clinical cancer research, 2005-12, Vol.11 (23), p.8418-8424

2005

Volltextzugriff (PDF)

Integrated genomic analysis suggests MLL3 is a novel candidate susceptibility gene for familial nasopharyngeal carcinoma

Cancer epidemiology, biomarkers & prevention, 2015-08, Vol.24 (8), p.1222-1228

2015

Volltextzugriff (PDF)

Inhibition of mTOR signaling and clinical activity of metformin in oral premalignant lesions

JCI insight, 2021-09, Vol.6 (17)

2021

Volltextzugriff (PDF)

Precision Chemo-Radiotherapy for HER2 Tumors Using Antibody Conjugates of an Auristatin Derivative with Reduced Cell Permeability

Molecular cancer therapeutics, 2019-10, Vol.19 (1), p.157-167

2019

Volltextzugriff (PDF)

Genetic profiling of advanced radioactive iodine-resistant differentiated thyroid cancer and correlation with axitinib efficacy

Cancer letters, 2015-04, Vol.359 (2), p.269-274

2015

Volltextzugriff (PDF)

Tumor cells fail to present MHC-II-restricted epitopes derived from oncogenes to CD4+ T cells

JCI insight, 2023-01, Vol.8 (2)

2023

Volltextzugriff (PDF)

Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck

Oral oncology, 2012-09, Vol.48 (9), p.887-892

2012

Volltextzugriff (PDF)

Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition

Molecular oncology, 2013-06, Vol.7 (3), p.359-368

2013

Volltextzugriff (PDF)

Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial

Trials, 2014-11, Vol.15 (1), p.469-469, Article 469

2014

Volltextzugriff (PDF)

Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy

BMC cancer, 2014-06, Vol.14 (1), p.473-473, Article 473

2014

Volltextzugriff (PDF)

Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide

Clinical cancer research, 2015-11, Vol.21 (22), p.5092-5099

2015

Volltextzugriff (PDF)

1 – 25 von 35

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(34)
Mit Volltextzugriff
(33)

Publikationsform

Artikel
(35)

Sprache

Englisch
(35)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(31)
Science & Technology
(31)
Humans
(27)
Oncology
(23)
Female
(11)
Aged
(10)
Male
(10)
Middle Aged
(10)
Adult
(9)
Antineoplastic Agents - Therapeutic Use
(8)
Carcinoma, Squamous Cell - Drug Therapy
(7)
Head And Neck Neoplasms - Drug Therapy
(7)
Head And Neck Neoplasms - Therapy
(7)
Treatment Outcome
(6)
Biological And Medical Sciences
(5)
Head And Neck Cancer
(5)
Head And Neck Neoplasms - Mortality
(5)
Head And Neck Neoplasms - Pathology
(5)
Medical Sciences
(5)
Mutation
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Clinical Cancer Research
(7)
Jci Insight
(3)
The Lancet Oncology
(3)
Cancer
(2)
Head & Neck
(2)
Bmc Cancer
(1)
Ca
(1)
Ca: A Cancer Journal For Clinicians
(1)
Cancer Epidemiology, Biomarkers & Prevention
(1)
Cancer Letters
(1)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study

Thyroid cancer: burden of illness and management of disease

American Cancer Society Head and Neck Cancer Survivorship Care Guideline

Role of B Cells in Responses to Checkpoint Blockade Immunotherapy and Overall Survival of Cancer Patients

Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas

Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer

Role of molecular markers in the management of head and neck cancers

Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer

Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies

Lenvatinib in Advanced, Radioactive Iodine-Refractory, Differentiated Thyroid Carcinoma

Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: TrilynX phase III study design

Modifiable risk behaviors in patients with head and neck cancer

Single sample expression-anchored mechanisms predict survival in head and neck cancer

Diarrhea associated with afatinib: an oral ErbB family blocker

Phase II Trial of Gefitinib 250 mg Daily in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

Integrated genomic analysis suggests MLL3 is a novel candidate susceptibility gene for familial nasopharyngeal carcinoma

Inhibition of mTOR signaling and clinical activity of metformin in oral premalignant lesions

Precision Chemo-Radiotherapy for HER2 Tumors Using Antibody Conjugates of an Auristatin Derivative with Reduced Cell Permeability

Genetic profiling of advanced radioactive iodine-resistant differentiated thyroid cancer and correlation with axitinib efficacy

Tumor cells fail to present MHC-II-restricted epitopes derived from oncogenes to CD4+ T cells

Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck

Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition

Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial

Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy

Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide

Suchergebnisse filtern